Delivery Order SPE2DB25D3012-SPE2DB25FWYSH
- Not listed
- The Defense Logistics Agency awarded a $41,609.70 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 ml pen injectors with an ultimate completion date of July 21, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and specifies performance at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $15,470.70 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical products...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $36,218.76 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors. The contract, awarded July 18, 2025, with an ultimate completion date of July 21, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award to this major pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for...
- The Defense Logistics Agency awarded a $45,173.75 delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injectors on July 18, 2025, with performance completion targeted for July 21, 2025. This firm fixed-price delivery order represents a pediatric and adult immunosuppressant medication used to treat moderate-to-severe atopic dermatitis, asthma, and eosinophilic conditions. The award was not set-aside and was competitively awarded through an open procurement...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at approximately $38.2K on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. This non-set-aside, firm fixed price delivery order is scheduled for completion by July 21, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe eczema, asthma, and...
- The Defense Logistics Agency awarded a $13,665.42 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent (dupilumab) 300 mg/2 mL pen injectors. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award, and specifies a completion date of July 21, 2025. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a discrete fulfillment...
- The Defense Logistics Agency awarded a $12,949.95 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units). This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-set-aside award. The products will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $8,920.52 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen (2 ml) pharmaceutical supplies with an ultimate completion date of July 21, 2025. This non-set-aside, competitively awarded contract represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at approximately $1 billion through December 2026. The place of performance...
- The Defense Logistics Agency awarded a $41,453.26 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Dupixent 300 mg/2 ml pens. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $10,777.92 to AmerisourceBergen Drug Corp for the supply of Dupixent (dupilumab) 300 mg/2 mL syringes on July 18, 2025, with completion scheduled for July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWYSHDelivery Order
The Defense Logistics Agency awarded a $46,389.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent (dupilumab) 300 mg/2 mL pen auto-injectors on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-set-aside contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999.9 million ceiling value and runs through December 2026. Dupixent is a biologic immunosuppressant medication indicated for moderate-to-severe atopic dermatitis, eosinophilic conditions, and asthma, and this procurement supports the military healthcare system's pharmaceutical supply chain. AmerisourceBergen serves as a critical prime pharmaceutical vendor for the Defense Health Agency and other federal healthcare systems, maintaining an extensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains. This delivery order exemplifies the company's role in the DLA's global pharmaceutical support operations, enabling rapid fulfillment of specialty medication requirements for military personnel and veterans.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.4k | 7/18/25 |